#USA #Redwood City #CRISPR #Synthego #Agilent

Synthego Celebrates Supreme Court’s Invalidation of Agilent's CRISPR Patents

Synthego, a trailblazer in genome engineering, expressed its gratitude following the U.S. Supreme Court's decision to uphold the invalidation of two patents held by Agilent Technologies related to CRISPR technology. This landmark ruling signifies the end of a protracted legal battle, allowing researchers greater freedom to advance gene-editing technologies.

The Supreme Court’s ruling, which denied Agilent's petition for a writ of certiorari, validates an earlier decision made by the U.S. Court of Appeals for the Federal Circuit. This ruling confirmed the Patent Trial and Appeal Board's determination that Agilent's patents, numbering 10,337,001 and 10,900,034, were indeed unpatentable. Both patents focused on specific chemical modifications of guide RNAs (gRNAs), which are crucial in CRISPR-Cas gene editing processes.

Craig Christianson, CEO of Synthego, commented on the significance of this ruling, stating, "We are deeply grateful for this final resolution. Our pursuit of this challenge was driven by a commitment to the broader scientific community. By clearing the patent thicket surrounding critical gene-editing modifications, we aim to empower researchers and developers in their innovation pursuits without the hindrance of invalid patent claims."

The conclusion of this case occurs at a vital time for Synthego, which is aggressively expanding its leadership in the cell and gene therapy space. The company is also innovating new tools that support molecular biology and diagnostic development. Their recent advancements in high-fidelity nucleases, such as hfCas12Max and eSpOT-ON proprietary enzymes, exemplify this mission.

Christianson further remarked, "This result aligns perfectly with our mission to accelerate the path from discovery to cure. Our introduction of novel nucleases and CRISPR technologies is inspired by the potential to foster a more open intellectual property environment, which will benefit not only the industry but, most importantly, the patients awaiting transformative therapies."

The invalidation of Agilent's patents eliminates a major barrier to essential gRNA modifications, paving the way for unencumbered innovation in CRISPR-based research and therapeutic applications. With the appeals process fully exhausted, Synthego reinforces its commitment to advancing genome engineering and supporting scientific discovery in life sciences.

About Synthego

Synthego is a pioneering biotechnology company at the vanguard of synthetic biology and genome engineering. Its dedication to providing researchers with state-of-the-art tools and expertise fosters accelerated scientific discovery. Recently, the company has expanded into molecular and clinical diagnostic reagents, solidifying its role as a leader in the life sciences sector.

For additional information, please visit Synthego's website.